
What to Look for When Abbott Labs (ABT) Reports Q2 Earnings
NEW YORK (TheStreet) -- Abbott Laboratories (ABT) - Get Report will report 2016 second quarter financial results before the market open on Wednesday, and analysts are projecting a year-over-year rise in both earnings and revenue.
Analysts surveyed by Thomson Reuters are modeling adjusted earnings of 53 cents per share on $5.24 billion in revenue for the quarter.
Last year the Abbott Park, IL-based healthcare company reported adjusted earnings of 52 cents per share on revenue of $5.17 billion for the 2015 second quarter.
"For 2016, Abbott is likely to continue to drive meaningful positive operating leverage with potentially modest sales growth acceleration as the company absorbs pending acquisitions including Alere (ALR) and St. Jude's Medical (STJ)," Leerink wrote in a note released earlier today.
Both of the deals could drive sales and per-share earnings growth as Abbott becomes a "more formidable player" in "medtech" and diagnostics with its expanded offerings, Leerink added.
The firm has a "market perform" rating and $45 price target on shares.
Abbott stock is up 0.07% to $42.13 in Monday afternoon trading.
Separately, TheStreet Ratings team rates the stock as a "hold" with a ratings score of C+.
Abbott's strengths such as its reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and expanding profit margins are countered by weaknesses including deteriorating net income, weak operating cash flow and a generally disappointing performance in the stock itself.
You can view the full analysis from the report here: ABT
TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this article's author.










